AUTL vs ILMN vs BRKR vs FATE

For growth investors, Autolus Therapeutics plc (AUTL) is the stronger pick with 496.

0% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). Illumina, Inc. (ILMN) offers the better valuation at 25. 5x trailing P/E (26. 8x forward), making it the more compelling value choice. Analysts rate Autolus Therapeutics plc (AUTL) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Bruker Corporation is actually cheaper at 20.

7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Bruker Corporation (BRKR) delivered a total return of -35.

5%, compared to -96. 8% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: BRKR returned +67. 1% versus AUTL's -93. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Illumina, Inc.

(ILMN) is the lower-risk stock at 1. 23β versus Fate Therapeutics, Inc. 's 2. 17β — meaning FATE is approximately 76% more volatile than ILMN relative to the S&P 500. On balance sheet safety, Autolus Therapeutics plc (AUTL) carries a lower debt/equity ratio of 12% versus 94% for Illumina, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Autolus Therapeutics plc (AUTL) is pulling ahead at 496.

0% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to -119. 7% for Bruker Corporation. Over a 3-year CAGR, AUTL leads at 88. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Illumina, Inc.

(ILMN) is the more profitable company, earning 19. 6% net margin versus -21. 8% for Autolus Therapeutics plc — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ILMN leads at 19. 9% versus -23. 9% for AUTL. At the gross margin level — before operating expenses — ILMN leads at 66. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Bruker Corporation (BRKR) trades at 20.

7x forward P/E versus 26. 8x for Illumina, Inc. — 6. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FATE: 1525. 5% to $39. 50.

In this comparison, BRKR (0.

3% yield) pays a dividend. AUTL, ILMN, FATE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Illumina, Inc.

(ILMN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 23)). Autolus Therapeutics plc (AUTL) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ILMN: +0. 7%, AUTL: -93. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AUTL is a small-cap high-growth stock; ILMN is a mid-cap quality compounder stock; BRKR is a small-cap quality compounder stock; FATE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.